Browse by Poster Presenter

Skip to main content

ISOP ACoP 2025 Annual Conference Main banner

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

S
Salem, Ahmed

AsztraZeneca
(M-001) Prediction of Percent Free Nerve Growth Factor Suppression following Administration of MEDI7352, a Bispecific Fusion Protein for Dual Targeting of NGF and TNFα, in Patients with Painful Diabetic Neuropathy and Osteoarthritis
Ahmed Salem
Favorite
(M-002) Population Pharmacokinetic Modeling of MEDI7352, a Bispecific Fusion Protein for Dual Targeting of NGF and TNFα, in Patients with Painful Diabetic Neuropathy and Painful Osteoarthritis of the Knee
Ahmed Salem
Favorite
Sale, Mark

Certara
(T-018) Constrained Multi-Objective optimization population PK model selection in NLME and RDarwin.
Mark Sale
Favorite
Samiotakis, Antonios

AbCellera Biologics Inc.
(S-035) Mechanistic insights on diverse in vivo tumor efficacy outcomes for bispecific T-cell engagers using a quantitative systems pharmacology model
Antonios Samiotakis
Favorite
Samtani, Mahesh

Janssen R&D, USA
(S-077) Population Pharmacokinetic & Exposure-Response Analysis After Subcutaneous Administration of Guselkumab in Pediatric Participants with Moderate to Severe Plaque Psoriasis
Mahesh Samtani
Favorite
Sano, Yamato

Pfizer R&D Japan
(M-036) Mechanistic Insights by Combining Quantitative Systems Pharmacology (QSP) and Machine Learning: An Inflammatory Bowel Disease Case Study
Yamato Sano
Favorite
Santulli, Andrew

Enhanced Pharmacodynamics, LLC
(T-042) SimKid: An R package for Simulation of Virtual Pediatric Subjects
Andrew Santulli
Favorite
Schaller, Stephan

ESQlabs, GmbH
(T-114) Open-Source Modeling of Anti-Tuberculosis Drug-Induced Cardiac Risks for Safe Dose Prediction
Stephan Schaller
Favorite
Schneck, Karen

Eli Lilly and Company
(T-030) PK/PD/PD Models Enable Quantitative Insights into the Exposure-Efficacy Relationships of Tirzepatide for Treatment of Obstructive Sleep Apnea
Karen Schneck
Favorite
Schulz Pauly, Julia

Amgen
(T-073) A PK/PD Model to Evaluate Uricosuric Clinical Efficacy versus Therapeutic Window for Treatment of Gout
Julia Schulz Pauly
Favorite
Seirin-Lee, Sungrim

Kyoto University
(T-116) Inference of Pathological States from Skin Eruption Morphology for Drug Efficacy Evaluation and Personalized Treatment in Skin Disease
Sungrim Seirin-Lee
Favorite
Shah, Millie

Biogen
(M-037) A quantitative systems pharmacology model of felzartamab, an anti-CD38 antibody, to link immune cell and pharmacodynamic responses in immune mediated diseases
Millie Shah
Favorite
Shahraz, Azar

AstraZeneca
(M-028) A Pharmacometrics Strategy for Ensuring Compatibility of Exposure-Response Analysis with Clinical Study Report: Enhancing Accuracy, Traceability, and Transferability Through Variable Mapping Specification (VMS)
Azar Shahraz
Favorite
Shah, Zeel

Bristol Myers Squibb
(T-029) A Model-Based Meta-Analysis Framework to Predict and Manage ADC-Related Grade 3+ Neutropenia Across Clinical Studies
Zeel Shah
Favorite
Shaik, Jafar Sadik

Johnson & Johnson Innovative Medicine
(T-083) Exposure-Response Analysis of Guselkumab in Induction Studies in Adults with Moderately to Severely Active Ulcerative Colitis in the QUASAR Program
Jafar Sadik Shaik
Favorite
Shannar, Ahmad

Rutgers - The State University of New Jersey
(T-037) Investigating tissue distribution of curcumin using Physiologically-based pharmacokinetic (PBPK) approach
Ahmad Shannar
Favorite
Shao, Shuai

Sanofi, Morristown, NJ USA
(M-069) Population Pharmacokinetic Analysis of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease
Shuai Shao
Favorite
(T-079) Population Pharmacokinetic Analysis to Characterize Pharmacokinetics of Sarilumab in Pediatric Participants with Polyarticular-Course Juvenile Idiopathic Arthritis
Shuai Shao
Favorite
Shapiro, Monica

Pfizer, Inc
(M-090) Pharmacoequivalence vs Bioequivalence: A role for MIDD analysis in bioequivalence studies
Monica Shapiro
Favorite
Sheng, Jennifer

Clinical Pharmacology and Pharmacometrics, Incyte
(S-111) Re-Purposing Bispecific Antibodies in Autoimmune Diseases: MIDD Based Dose Optimization Strategies
Jennifer Sheng
Favorite
Shenkoya, Babajide

University of Maryland School of Pharmacy, Baltimore, MD, USA
(T-109) A Multi-route, Multi-formulation Population Pharmacokinetic Framework for THC and 11-OH-THC Reflecting Real-World Use
Babajide Shenkoya
Favorite
Sherfey, Jason

Bristol Myers Squibb
(S-063) A Translational Quantitative Systems Pharmacology Framework For Alpha-Synuclein-Targeted Parkinson’s Therapies Integrating Pharmacokinetics, Neuronal Biophysics, And Pathological Network Oscillations
Jason Sherfey
Favorite
Sidi, Jonathan

Sanofi
(M-066) Model-informed Assessment of the Impact of Relaxing the high-sensitivity C-reactive protein Inclusion Criteria on Patient Enrollment and Efficacy Signal in Rheumatoid Arthritis Clinical Trial Design
Jonathan Sidi
Favorite
Siler, Scott

Simulations Plus
(M-100) Development of a Quantitative Systems Toxicology Model to Predict Drug-Induced Liver Injury in Pediatrics
Scott Siler
Favorite
Sinha, Jaydeep

Daiichi-Sankyo, Inc., USA
(T-100) Exposure-Response Analysis of Datopotamab Deruxtecan (Dato-DXd) in Combination with Pembrolizumab with or without Platinum Chemotherapy in Patients with Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Jaydeep Sinha
Favorite
Skataric, Maja

Merck
(T-032) Navigating Challenges in Dose-Exposure-Response Analysis in the Presence of Confounding Associated with Titrated Drug Regimens
Maja Skataric
Favorite
Smania, Giovanni

Pharmetheus AB
(S-075) Exposure-Overall Survival Analysis for Quizartinib in Newly Diagnosed Patients with FLT3-Internal-Tandem-Duplication-Positive Acute Myeloid Leukemia
Giovanni Smania
Favorite
Soliman, Amira

Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida, Orlando, Florida, USA
(T-036) Leveraging PBPK Modeling for Bioavailability Enhancement: Insights from In Vitro Dissolution and Cocrystallization Studies
Amira Soliman
Favorite
Song, Eric

Genmab
(T-039) Predicting Tumor Growth Dynamics and Overall Survival with Deep Learning Model
Eric Song
Favorite
Spinosa, Phillip

Genentech, Inc.
(T-007) Development of a Unified QSP Framework to Characterize the Pharmacokinetics of TCBs
Phillip Spinosa
Favorite
Srivastava, Ashish

University of Tennessee Health Science Center
(T-063) Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of a Novel, Directly Acting Antiviral, BDGR-251, in EEEV Infected Mice
Ashish Srivastava
Favorite
Stephens, Hunter

Certara
(M-108) Using Modeling and Simulation to Assess the Impact of the Pharmacokinetics and Biodistribution on the Absorbed and Biologically Effective Dose for Radioligand Therapies
Hunter Stephens
Favorite
Stodtmann, Sven

AbbVie
(M-024) A Population PK-PD Model-Informed Approach to Guide Formulation Development
Sven Stodtmann
Favorite
Subramanian, Kalyanasundaram

Differentia Biotech LTD
(S-061) Insights into Guide-Effector Antigen Interaction for Bispecific Antibody Design Using a Mechanistic Model
Kalyanasundaram Subramanian
Favorite
Sung, Kyeri

Sanofi
(M-076) Machine learning approach links QSP virtual populations with key lesion types and clinical scoring in hidradenitis suppurativa
Kyeri Sung
Favorite
Sun, Steven

UCSD
(S-105) POPULATION PHARMACOKINETIC (POPPK) MODELING OF IRINOTECAN AND SN38 IN PARTICIPANTS WITH METASTATIC COLORECTAL CANCER (MCRC) IN PHASE 2 AND 3 STUDIES: A SEQUENTIAL PARENT-METABOLITE MODEL
Steven Sun
Favorite
Suriyapakorn, Bovornpat

University of Minnesota
(M-105) Designing Optimal Pharmacokinetic Sampling Strategies for Ketamine in Established Status Epilepticus: A Model-Based Simulation Study to Support the Ketamine Add-On Therapy for Established Status Epilepticus Treatment Trial
Bovornpat Suriyapakorn
Favorite
Susilo, Monica

Genentech
(T-091) gQSPTwin: A MATLAB-Based Application for Automation and Standardization of the QSP Digital Twin Generation Workflow
Monica Susilo
Favorite
Sutton, Karyn

Bristol Myers Squibb
(S-066) Right-Sizing Models: A Model Reduction Approach Applied to Models of the Treatment of Solid Tumors by Protein Degraders
Karyn Sutton
Favorite